Longeveron licenses stem cell patent for heart disease treatment

Published 21/07/2025, 14:28
Longeveron licenses stem cell patent for heart disease treatment

MIAMI - Longeveron Inc. (NASDAQ:LGVN), a $23 million market cap biotechnology company currently considered undervalued according to InvestingPro analysis, has licensed a U.S. patent for stem cell technology from the University of Miami that could advance treatments for heart diseases, the company announced Monday.

The licensed patent (12,168,028 B2) protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells. These specialized cells can differentiate into human cardiac muscle cells while potentially avoiding the risk of ventricular arrhythmias that has hindered previous stem cell approaches.

"This technology provides a solution to one of the most difficult barriers to the implementation of induced pluripotent stem cells technology in the cardiovascular space," said Joshua Hare, Co-founder, Chief Science Officer, and Chairman at Longeveron. The company maintains a strong liquidity position with a current ratio of 5.6x and holds more cash than debt on its balance sheet, according to InvestingPro data.

The patented technology works by selecting cells destined to become cardiomyocytes while eliminating cells with electrical automaticity found in conduction tissue. This approach allows for new contractile tissue without the risk of causing dangerous heart rhythm abnormalities.

Longeveron, a clinical stage regenerative medicine biotechnology company, believes the technology could be applicable to a broad range of cardiovascular diseases in adults and rare pediatric conditions.

The company’s lead investigational product, laromestrocel (Lomecel-B), is currently being developed for hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.

This announcement comes after Longeveron recently received IND approval for pediatric dilated cardiomyopathy, according to the press release statement. While the company shows promising technological advances, InvestingPro data indicates analysts anticipate a sales decline in the current year. Discover more insights and 6 additional ProTips with an InvestingPro subscription, including detailed analysis of the company’s financial health and growth prospects.

In other recent news, Longeveron Inc. has announced several significant developments. The company reported a 30% decline in revenue for the first quarter of 2025 compared to the same period in 2024, with revenues falling to $400,000. The net loss increased to $5 million, up from $4 million in the previous year. Despite these financial challenges, Longeveron received U.S. FDA approval for its Investigational New Drug (IND) application for laromestrocel, a stem cell therapy targeting pediatric dilated cardiomyopathy. This approval allows Longeveron to move directly to a Phase 2 pivotal registration clinical trial expected to start in 2026. Additionally, Longeveron completed enrollment in its Phase 2b trial for Hypoplastic Left Heart Syndrome (HLHS), with top-line results anticipated in the third quarter of 2026. The company appointed Than Powell as Chief Business Officer to lead its business strategy, particularly in its Alzheimer’s disease program and international efforts for the HLHS program. These developments indicate Longeveron’s focus on advancing its clinical trials and potential market opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.